(Boursier.com) — MaaT Pharmaa late-stage clinical-stage biotechnology company and leader in the development of Microbiome Ecosystem Therapies (MET) aimed at improving the survival of patients with cancer, today announced expanded results in 111 patients with aGvHD in the of the EAP program (30 more patients included in the program compared to the previous year) for MaaT013 and the design of the Phase 2b trial evaluating MaaT033 dedicated to improving the overall survival of patients who received an allogeneic hematopoietic stem cell transplant (allo-HSCT) were selected for a poster presentation at the 65th Annual Meeting of the American Society of Hematology (ASH), which will be held December 9-12, 2023 in San Diego, California, USA.
This is the seventh consecutive year that the company’s data and clinical activities have been selected to be presented at the ASH Annual Meeting, a leading global event in the field of malignant and non-malignant hematology, demonstrating the interest continued by clinicians for microbiota modulation approaches in the field of hemato-oncology.
In accordance with the conference embargo policy, MaaT Pharma will detail the results presented through a press release on Monday, December 11, 2023. The Company will also organize a dedicated investor webcast on Monday, December 18, 2023 at 6:00 p.m. CET ( more information to come soon).
The EAP results include data from 111 patients with steroid-dependent or steroid-resistant aGvHD treated with MaaT013 after previously unsuccessfully receiving 1 to 6 lines of treatment. MaaT013 is currently being evaluated in a pivotal, single-arm, open-label Phase 3 trial in Europe (n=75) in patients with gastrointestinal aGvHD resistant to corticosteroids and ruxolitinib treatment. The company announced, in October 2023, the positive conclusions of the DSMB, for this Phase 3 trial, including a favorable benefit-risk ratio, with a good safety profile and positive preliminary efficacy results. To date, MaaT013 has been safely administered to more than 170 patients in Europe in clinical trials and the EAP program.
The company is providing an update for MaaT033, a microbiota ecosystem adjuvant therapy oral capsule, and will share the design of the Phase 2b trial, the largest randomized control arm study for a microbiota therapy in hematology to date. with the recruitment of 387 patients, evaluating the effectiveness of MaaT033 in improving the overall survival of patients receiving allo-HSCT.
©2023 Boursier.com